study of the safety, pharmacokinetics, pharmacodynamics, and efficacy of duvortuxizumab (jnj-64052781) plus ibrutinib in lymphoma

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell

Summary: the purpose of this study is to determine whether duvortuxizumab and ibrutinib can be combined safely and to establish the maximum tolerated dose (mtd) in part 1 and the recommended phase 2 dose (rp2d) and to further explore the safety of duvortuxizumab in combination with ibrutinib at the rp2d in participants with diffuse large b-cell lymphoma (dlbcl), follicular lymphoma (fl), mantle cell lymphoma (mcl), and chronic lymphocytic leukemia (cll) in part 2.

this is an open-label (identity of study drug will be known to participant and study staff), multicenter (when more than one hospital or medical school team work on a medical research study), phase 1b study. the purpose of this study is to see if duvortuxizumab in combination with ibrutinib is safe and useful for treating participants with b-cell malignancies. this study will be conducted in 2 parts: part 1: dose optimization and part 2: dose expansion. part 1 will determine what dose of duvortuxizumab can be given safely with the standard dose of ibrutinib to participants with previously treated b-cell malignancies. part 2 will look at how previously treated dlbcl, fl, mcl, and cll participants respond to a safe dose of duvortuxizumab in combination with ibrutinib. part 2 will also test whether the dose from part 1 is an effective cancer therapy. the study consists of a screening phase, an ibrutinib run-in phase (part 2 only), a combination (duvortuxizumab plus ibrutinib) treatment phase (day 1, cycle 1 and continues until the completion of the end-of-treatment visit), end-of-treatment visit (30 days (+7 days) after the last dose of study drug), and post-treatment follow-up phase. the end of the study will be defined as 12 months after the last participant has received the first dose of study treatment. participants' safety will be monitored throughout the study.

Eligibility criteria:
inclusion criteria: * the participant has a b-cell malignancy (diffuse large b-cell lymphoma \[dlbcl\], follicular lymphoma \[fl\], mantle cell lymphoma \[mcl\], or chronic lymphocytic leukemia \[cll\]) with tumor progression following at least one (mcl and cll) or two (dlbcl and fl) prior standard therapies * the participant has a radiographically measurable tumor that requires treatment according to the treating physician * the participant is able to carry out daily life activities with significant difficulty * the participant has adequate organ and blood cell counts * sexually active participants must use medically acceptable methods of contraception during the course of the study exclusion criteria: * the participant has a brain tumor or significant side effects, including severe neurological side effects, from a previous anti-cancer treatment * current severe, uncontrolled systemic disease including an ongoing, active infection or history of clinically significant heart problems * history of autoimmune disease, allogeneic hematopoietic stem cell transplant, or organ transplant * the participant has received any of the following: ibrutinib or other bruton's tyrosine kinase (btk) inhibitor at any time; an agent targeting cd19-positive cells or cd3-expressing t cells at any time; or warfarin, a vitamin k antagonist, or a blood transfusion (red blood cells and/or platelets) within 1 week of starting the study * the participant is pregnant, breastfeeding, or planning to become pregnant or father a child

Keywords: b-cell, malignancy lymphoma, large b-cell, diffuse lymphoma, mantle-cell lymphoma, follicular lymphocytic, chronic, b-cell jnj-64052781 ibrutinib